Cochrane · systematic review · CD004302

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease

Bongioanni, P, Reali, C, Sogos, V · Cochrane Database of Systematic Reviews · 2004 · Cochrane Library

NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 7 · 100%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Any CNTF versus placebo for amyotrophic lateral sclerosis or motor neuron disease

Population: patients with amyotrophic lateral sclerosis or motor neuron disease
7 questions
OutcomeEffectEvidenceStatus / GRADE
Deaths
Any CNTF vs placebo
RR 1.07 [0.81, 1.41]2 studies · 1300 participantsHigh
Muscle strength change from baseline value of isometric muscle strength (combination megascore)
Any CNTF vs placebo
no estimate extracted2 studies · 1300 participantsHigh
Respiratory function (FVC %) change from baseline measures of forced vital capacity as a percentage of the predicted value (FVC %)
Any CNTF vs placebo
no estimate extracted2 studies · 1300 participantsHigh
Changes in quality of life (SIP) change in Sickness Impact Profile (SIP) scores (range from 0 = best health to 100 = worst health).
Any CNTF vs placebo
no estimate extracted1 study · 503 participantsHigh
Asthenia
Any CNTF vs placebo
RR 1.02 [0.81, 1.28]1 study · 570 participantsHigh
Nausea
Any CNTF vs placebo
RR 1.35 [0.92, 1.99]1 study · 570 participantsHigh
Increased salivation
Any CNTF vs placebo
RR 1.08 [0.78, 1.5]1 study · 570 participantsHigh